25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Medical Provider Refused to Hire Men and Retaliated Against an Applicant for Complaining, Federal Ag...
Read More >
For at least two decades, Pennsylvania law has recognized an exemption from strict liability for pre...
Read More >
On March 15, 2020, the long-awaited Paid Sick Days Act of the City of Pittsburgh (the Act) will go i...
Read More >
“The immunity provision of the Defend Trade Secrets Act creates serious risk for companies: A whist...
Read More >
In this episode of Excellence in Training, Shawn Rogers and I consider the establishing of your comp...
Read More >
On March 27, President Trump signed the Coronavirus Aid, Relief and Economic Security Act (CARES Act...
Read More >